Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
32 hedge funds and large institutions have $3.08M invested in Acorda Therapeutics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 31 → 32 (+1)
43% less capital invested
Capital invested by funds: $5.42M → $3.08M (-$2.34M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
+$2.13M |
| 2 |
CCA
Canyon Capital Advisors
Dallas,
Texas
|
+$484K |
| 3 |
Millennium Management
New York
|
+$240K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$191K |
| 5 |
Renaissance Technologies
New York
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$747K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$163K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$127K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$32K |
| 5 |
BlackRock
New York
|
-$23.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $3K | +$1.94K | +109 | +38% |
|
27
Russell Investments Group
London,
United Kingdom
| $2K | – | – | – |
|
28
Morgan Stanley
New York
| $2K | +$498 | +28 | +12% |
|
|
29
Point72 Asset Management
Stamford,
Connecticut
| – | -$747K | -23,214 | Closed |
|
|
30
Dimensional Fund Advisors
Austin,
Texas
| – | -$32K | -988 | Closed |
|
31
Jane Street
New York
| – | -$22K | -675 | Closed |
|
32
Citigroup
New York
| – | -$3K | -83 | Closed |
|
33
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -38 | Closed |
|
34
Osaic Holdings
Scottsdale,
Arizona
| – | -$71 | -4 | Closed |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$36 | -2 | -12% |
|
36
JP Morgan Chase
New York
| – | +$18 | +1 | New |
|
ACOR Hedge Fund Activity: Q2 2022 in Review
32 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q2 2022, worth a combined $3.08M — down 43% from $5.42M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ACOR positions and 8 closed out — a net gain of 2 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Davidson Kempner Capital Management, opening a new position worth an estimated $2.13M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $747K sold.
- 32 institutional investors held Acorda Therapeutics (ACOR) as of Q2 2022, up from 31 in Q1 2022.
- Funds reported $3.08M of Acorda Therapeutics stock for Q2 2022, down 43% quarter-over-quarter.
- 10 funds opened new Acorda Therapeutics positions in Q2 2022 and 8 closed out, a net change of +2 holders.
- The largest Acorda Therapeutics buyer in Q2 2022 was Davidson Kempner Capital Management, an estimated $2.13M added.
- The largest Acorda Therapeutics seller in Q2 2022 was Point72 Asset Management, an estimated $747K sold.
Based on aggregated 13F filings for Q2 2022.